Primary biliary cirrhosis: how should we evaluate new treatments?

Participants at a conference held at the Mayo Clinic in May 1994 reviewed the most promising agents and attempted to define more clearly the value of existing trial endpoints in the treatment of primary biliary cirrhosis. The conference focused on the use of four drugs--cyclosporin, colchicine, meth...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1994-05, Vol.343 (8909), p.1305-1306
Main Authors: Goddard, C.J.R., Warnes, T.W.
Format: Article
Language:English
Subjects:
Clinical Trials as Topic
Colchicine - therapeutic use
Cyclosporine - therapeutic use
Drug therapy
Health care
Humans
Liver cirrhosis
Liver Cirrhosis, Biliary - drug therapy
Liver Cirrhosis, Biliary - mortality
Medical research
Methotrexate - therapeutic use
Prognosis
Survival Analysis
Ursodeoxycholic Acid - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Participants at a conference held at the Mayo Clinic in May 1994 reviewed the most promising agents and attempted to define more clearly the value of existing trial endpoints in the treatment of primary biliary cirrhosis. The conference focused on the use of four drugs--cyclosporin, colchicine, methotrexate and ursodeoxycholic acid.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(94)92461-9